US Patent

US9040528 — Chemical compounds 542

Method of Use · Assigned to AstraZeneca AB · Expires 2029-10-13 · 3y remaining

Vulnerability score 81/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects chemical compounds and their salts, as well as methods for using them to treat bacterial infections.

USPTO Abstract

The present invention relates to compounds of Formula (I): to pharmaceutically acceptable salts thereof, to methods of using them to treat bacterial infections, and to methods for their preparation.

Drugs covered by this patent

zoliflodacin (ZOLIFLODACIN)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4369`	—	zoliflodacin

Patent Metadata

Patent number: US9040528
Jurisdiction: US
Classification: Method of Use
Expires: 2029-10-13
Drug substance claim: No
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.